GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
British Journal of Clinical Pharmacology2016Vol. 83(4), pp. 732–741
Citations Over TimeTop 10% of 2016 papers
Oliver von Richter, Andrej Skerjanec, Miguel Afonso Filipe, Sabine Heinrich, Johann Poetzl, Heike Woehling, Maria Velinova, Annelize Koch, Dmitrij Kollins, Lars Macke, G. Wuerth
Abstract
The PK of GP2015 was similar to ETN, demonstrating bioequivalence. The safety profile of GP2015 was consistent with previous reports for ETN. The GP2015 AI provided equivalent dosing and tolerability to the GP2015 PFS.
Related Papers
- → Biosimilar insulins: a E uropean perspective(2014)30 cited
- → Innovation, Patents and Biologics: The Road to Biosimilar Competition: Factors Influencing Investment, Business Decisions and Marketing of Biosimilars(2018)3 cited
- → Biosimilars markets: US and EU compared(2020)3 cited
- → Biosimilar Drugs(2012)3 cited
- → Prospects and Challenges for the Commercialization of Biosimilars: Perspectives from the EU, Japan, and the US(2016)